<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(B) OR 12(G) OF THE
SECURITIES EXCHANGE ACT OF 1934
---------------------
ANTHRA PHARMACEUTICALS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C>
DELAWARE 22-3007972
(STATE OR OTHER JURISDICTION (I.R.S. EMPLOYER
OF INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER)
103 CARNEGIE CENTER, SUITE 102 08540
PRINCETON, NEW JERSEY (ZIP CODE)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
</TABLE>
---------------------
If this form relates to the registration of a class of securities pursuant
to Section 12(b) of the Exchange Act and is effective pursuant to General
Instruction A.(c), check the following box. |_|
If this form relates to the registration of a class of securities pursuant
to Section 12(g) of the Exchange Act and is effective pursuant to General
Instruction A.(d), check the following box. |X|
Securities Act registration statement file number to which this form
relates: 333-47725.
Securities to be registered pursuant to Section 12(b) of the Exchange Act: None
Securities to be registered pursuant to Section 12(g) of the Exchange Act:
Common Stock, $0.01 par value per share
(Title of class)
<PAGE> 2
ITEM 1. DESCRIPTION OF REGISTRANT'S SECURITIES TO BE REGISTERED.
A complete description of the Common Stock, $0.01 par value per share,
of Anthra Pharmaceuticals, Inc. (the "Registrant"), which is to be
registered hereunder is contained under the caption "Description of
Capital Stock" in the Registration Statement on Form S-1 (File No.
333-47725) filed by the Registrant with the Securities and Exchange
Commission on March 11, 1998, as amended from time to time. Such
description is hereby incorporated by reference.
ITEM 2. EXHIBITS.
The following exhibits are filed herewith (or incorporated by reference
as indicated below):
<TABLE>
<CAPTION>
Exhibit Number Description
-------------- -----------
<S> <C>
1 Amended and Restated Certificate of Incorporation of
the Registrant. Reference is made to Exhibit 3.1 to
the Registration Statement on Form S-1 (File No.
333-47725) of the Registrant, as amended.
2 Bylaws of the Registrant. Reference is made to
Exhibit 3.2 to the Registration Statement on Form S-1
(File No. 333-47725) of the Registrant, as amended.
3 Specimen Common Stock Certificate. Reference is made
to Exhibit 4.2 to the Registration Statement on Form
S-1 (File No. 333-47725) of the Registrant, as
amended.
4 Fifth Amended and Restated Registration Rights
Agreement dated October 14, 1997, by and among the
Company, Advanced Technology Ventures III, L.P.,
Sevin Rosen Fund III, L.P., Allstate Insurance
Company, Allstate Life Insurance Company, Aperture
Associates, L.P., Schering Berlin Venture
Corporation, Prodesfarma, S.A. and Nycomed Pharma AS.
Reference is made to Exhibit 4.3 to the Registration
Statement on Form S-1 (File No. 333-47725) of the
Registrant, as amended.
5 1990 Stock Plan, as amended. Reference is made to
Exhibit 10.13 to the Registration Statement on Form
S-1 (File No. 333-47725) of the Registrant, as
amended.
</TABLE>
2
<PAGE> 3
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange
Act of 1934, as amended, the Registrant has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereto duly
authorized.
ANTHRA PHARMACEUTICALS, INC.
By: /s/ Michael C. Walker
Name: Michael C. Walker
Title: President and Chief Executive Officer
(Principal Executive Officer)
Date: April 28, 1998
3
